vs
PREFORMED LINE PRODUCTS CO（PLPC）与VERACYTE, INC.（VCYT）财务数据对比。点击上方公司名可切换其他公司
PREFORMED LINE PRODUCTS CO的季度营收约是VERACYTE, INC.的1.2倍（$173.1M vs $140.6M），VERACYTE, INC.净利率更高（29.3% vs 4.9%，领先24.4%），VERACYTE, INC.同比增速更快（18.5% vs 3.6%），VERACYTE, INC.自由现金流更多（$48.8M vs $11.8M），过去两年VERACYTE, INC.的营收复合增速更高（20.5% vs 10.8%）
预成型线路产品公司（PLPC）研发、生产和销售适用于输配电、通信及可再生能源基建领域的工程硬件组件，服务全球多地的公用事业、网络运营商及工业客户，提供可提升网络可靠性与运营效率的解决方案。
Veracyte是一家领先的分子诊断企业，专注开发专有的基因组检测方案，可实现癌症及其他复杂疾病的早期精准检测，产品服务于医疗机构以优化临床决策，核心市场位于美国，正稳步拓展全球业务布局。
PLPC vs VCYT — 直观对比
营收规模更大
PLPC
是对方的1.2倍
$140.6M
营收增速更快
VCYT
高出15.0%
3.6%
净利率更高
VCYT
高出24.4%
4.9%
自由现金流更多
VCYT
多$37.0M
$11.8M
两年增速更快
VCYT
近两年复合增速
10.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $173.1M | $140.6M |
| 净利润 | $8.4M | $41.1M |
| 毛利率 | 29.8% | 72.5% |
| 营业利润率 | 6.8% | 26.4% |
| 净利率 | 4.9% | 29.3% |
| 营收同比 | 3.6% | 18.5% |
| 净利润同比 | -19.3% | 704.8% |
| 每股收益（稀释后） | $1.72 | $0.50 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PLPCVCYT
| Q4 25 | $173.1M | $140.6M | ||
| Q3 25 | $178.1M | $131.9M | ||
| Q2 25 | $169.6M | $130.2M | ||
| Q1 25 | $148.5M | $114.5M | ||
| Q4 24 | $167.1M | $118.6M | ||
| Q3 24 | $147.0M | $115.9M | ||
| Q2 24 | $138.7M | $114.4M | ||
| Q1 24 | $140.9M | $96.8M |
净利润PLPCVCYT
| Q4 25 | $8.4M | $41.1M | ||
| Q3 25 | $2.6M | $19.1M | ||
| Q2 25 | $12.7M | $-980.0K | ||
| Q1 25 | $11.5M | $7.0M | ||
| Q4 24 | $10.5M | $5.1M | ||
| Q3 24 | $7.7M | $15.2M | ||
| Q2 24 | $9.4M | $5.7M | ||
| Q1 24 | $9.6M | $-1.9M |
毛利率PLPCVCYT
| Q4 25 | 29.8% | 72.5% | ||
| Q3 25 | 29.7% | 69.2% | ||
| Q2 25 | 32.7% | 69.0% | ||
| Q1 25 | 32.8% | 69.5% | ||
| Q4 24 | 33.3% | 66.4% | ||
| Q3 24 | 31.1% | 68.2% | ||
| Q2 24 | 31.9% | 68.1% | ||
| Q1 24 | 31.3% | 64.5% |
营业利润率PLPCVCYT
| Q4 25 | 6.8% | 26.4% | ||
| Q3 25 | 7.4% | 17.4% | ||
| Q2 25 | 10.1% | -4.0% | ||
| Q1 25 | 8.8% | 2.5% | ||
| Q4 24 | 10.5% | 3.5% | ||
| Q3 24 | 7.1% | 10.4% | ||
| Q2 24 | 8.1% | 4.0% | ||
| Q1 24 | 8.2% | -4.8% |
净利率PLPCVCYT
| Q4 25 | 4.9% | 29.3% | ||
| Q3 25 | 1.5% | 14.5% | ||
| Q2 25 | 7.5% | -0.8% | ||
| Q1 25 | 7.8% | 6.2% | ||
| Q4 24 | 6.3% | 4.3% | ||
| Q3 24 | 5.2% | 13.1% | ||
| Q2 24 | 6.8% | 5.0% | ||
| Q1 24 | 6.8% | -1.9% |
每股收益（稀释后）PLPCVCYT
| Q4 25 | $1.72 | $0.50 | ||
| Q3 25 | $0.53 | $0.24 | ||
| Q2 25 | $2.56 | $-0.01 | ||
| Q1 25 | $2.33 | $0.09 | ||
| Q4 24 | $2.13 | $0.07 | ||
| Q3 24 | $1.54 | $0.19 | ||
| Q2 24 | $1.89 | $0.07 | ||
| Q1 24 | $1.94 | $-0.02 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $362.6M |
| 总债务越低越好 | $38.3M | — |
| 股东权益账面价值 | $475.5M | $1.3B |
| 总资产 | $653.6M | $1.4B |
| 负债/权益比越低杠杆越低 | 0.08× | — |
8季度趋势，按日历期对齐
现金及短期投资PLPCVCYT
| Q4 25 | — | $362.6M | ||
| Q3 25 | — | $315.6M | ||
| Q2 25 | — | $219.5M | ||
| Q1 25 | — | $186.1M | ||
| Q4 24 | — | $239.1M | ||
| Q3 24 | — | $274.1M | ||
| Q2 24 | — | $235.9M | ||
| Q1 24 | — | $209.2M |
总债务PLPCVCYT
| Q4 25 | $38.3M | — | ||
| Q3 25 | $36.0M | — | ||
| Q2 25 | $31.8M | — | ||
| Q1 25 | $29.1M | — | ||
| Q4 24 | $20.8M | — | ||
| Q3 24 | $27.2M | — | ||
| Q2 24 | $31.6M | — | ||
| Q1 24 | $55.0M | — |
股东权益PLPCVCYT
| Q4 25 | $475.5M | $1.3B | ||
| Q3 25 | $466.3M | $1.3B | ||
| Q2 25 | $460.7M | $1.2B | ||
| Q1 25 | $435.8M | $1.2B | ||
| Q4 24 | $422.3M | $1.2B | ||
| Q3 24 | $429.0M | $1.2B | ||
| Q2 24 | $416.2M | $1.1B | ||
| Q1 24 | $413.4M | $1.1B |
总资产PLPCVCYT
| Q4 25 | $653.6M | $1.4B | ||
| Q3 25 | $644.6M | $1.4B | ||
| Q2 25 | $631.5M | $1.3B | ||
| Q1 25 | $592.5M | $1.3B | ||
| Q4 24 | $573.9M | $1.3B | ||
| Q3 24 | $592.0M | $1.3B | ||
| Q2 24 | $572.6M | $1.2B | ||
| Q1 24 | $586.1M | $1.2B |
负债/权益比PLPCVCYT
| Q4 25 | 0.08× | — | ||
| Q3 25 | 0.08× | — | ||
| Q2 25 | 0.07× | — | ||
| Q1 25 | 0.07× | — | ||
| Q4 24 | 0.05× | — | ||
| Q3 24 | 0.06× | — | ||
| Q2 24 | 0.08× | — | ||
| Q1 24 | 0.13× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $21.9M | $52.6M |
| 自由现金流经营现金流 - 资本支出 | $11.8M | $48.8M |
| 自由现金流率自由现金流/营收 | 6.8% | 34.7% |
| 资本支出强度资本支出/营收 | 5.9% | 2.7% |
| 现金转化率经营现金流/净利润 | 2.60× | 1.28× |
| 过去12个月自由现金流最近4个季度 | $33.3M | $126.6M |
8季度趋势，按日历期对齐
经营现金流PLPCVCYT
| Q4 25 | $21.9M | $52.6M | ||
| Q3 25 | $18.9M | $44.8M | ||
| Q2 25 | $26.9M | $33.6M | ||
| Q1 25 | $5.7M | $5.4M | ||
| Q4 24 | $24.1M | $24.5M | ||
| Q3 24 | $9.4M | $30.0M | ||
| Q2 24 | $28.3M | $29.6M | ||
| Q1 24 | $5.8M | $-9.0M |
自由现金流PLPCVCYT
| Q4 25 | $11.8M | $48.8M | ||
| Q3 25 | $8.3M | $42.0M | ||
| Q2 25 | $18.6M | $32.3M | ||
| Q1 25 | $-5.3M | $3.5M | ||
| Q4 24 | $20.6M | $20.4M | ||
| Q3 24 | $5.8M | $27.7M | ||
| Q2 24 | $24.6M | $26.8M | ||
| Q1 24 | $1.8M | $-11.1M |
自由现金流率PLPCVCYT
| Q4 25 | 6.8% | 34.7% | ||
| Q3 25 | 4.7% | 31.8% | ||
| Q2 25 | 10.9% | 24.8% | ||
| Q1 25 | -3.6% | 3.1% | ||
| Q4 24 | 12.3% | 17.2% | ||
| Q3 24 | 3.9% | 23.9% | ||
| Q2 24 | 17.7% | 23.4% | ||
| Q1 24 | 1.3% | -11.5% |
资本支出强度PLPCVCYT
| Q4 25 | 5.9% | 2.7% | ||
| Q3 25 | 6.0% | 2.1% | ||
| Q2 25 | 4.9% | 1.0% | ||
| Q1 25 | 7.4% | 1.6% | ||
| Q4 24 | 2.1% | 3.5% | ||
| Q3 24 | 2.4% | 1.9% | ||
| Q2 24 | 2.7% | 2.4% | ||
| Q1 24 | 2.8% | 2.2% |
现金转化率PLPCVCYT
| Q4 25 | 2.60× | 1.28× | ||
| Q3 25 | 7.21× | 2.34× | ||
| Q2 25 | 2.12× | — | ||
| Q1 25 | 0.49× | 0.76× | ||
| Q4 24 | 2.30× | 4.80× | ||
| Q3 24 | 1.22× | 1.98× | ||
| Q2 24 | 3.02× | 5.16× | ||
| Q1 24 | 0.60× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PLPC
暂无分部数据
VCYT
| Testing | $135.8M | 97% |
| Products | $3.8M | 3% |
| Biopharmaceutical And Other | $686.0K | 0% |
